BioLineRx Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to BioLineRx Reports Third Quarter 2016 Financial Results
November 22, 2016 2:39 PM EST
Roth Capital affirms BioLineRx (Nasdaq: BLRX) with a Buy rating and $7 price target following Q3 results reported on Tuesday.
The analyst commented, We are encouraged by the multiple collaborations initiated between BLRX and biopharma in both clinical and preclinical staged projects, spanning multiple indications.
We believe that BL-8040 remains the lead value driver for BLRX with 1) partial results for the Phase II study of... More
November 22, 2016 8:07 AM EST
BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07).
The Company held $38.9 million in cash, cash equivalents and short-term bank deposits as of September 30, 2016.
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
...
More
